Submit to Cancers Review for Cancers Propose a Special Issue

Journal Browser

► Journal Browser

Pathophysiology and Treatment of Peritoneal Metastasis

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 October 2021) | Viewed by 20798

Share This Special Issue

Special Issue Editor

Prof. Dr. Kuno Lehmann

E-Mail Website
Guest Editor

Department of Surgery and Transplantation, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland
Interests: peritoneal metastasis; hyperthermic intraperitoneal chemotherapy; cytoreductive surgery; immune response

Special Issue Information

The treatment of peritoneal metastasis dramatically evolved over the last few years. In addition to the progress of medical oncology, providing novel and more effective combination regimens, cancer surgery successfully introduced cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as an innovative technical concept. In addition to radical surgery, HIPEC was introduced after complete CRS to enhance tumor eradication to a maximum. Over the last decade, significant survival benefits have been published for patients with peritoneal metastasis from colon cancer, appendix tumors, ovarian cancer, primary peritoneal mesothelioma, or gastric cancer, after CRS/HIPEC. This data, with few exceptions, originates from large registries, representing well selected patients. In several recent RCTs, however, the benefit of locoregional treatment, particularly HIPEC, has been unclear, or less than expected. In the same period, the evidence has grown that the pathophysiology of peritoneal metastasis differs from metastasis to the lung or liver. Taken together, there is a lack, and therefore an urgent need, for basic and translational research to better understand the pathophysiology of peritoneal metastasis and its treatment. In this Special Issue, we aim to highlight novel insights providing a better understanding of the disease, enabling novel concepts for the treatment of peritoneal metastasis.

Prof. Dr. Kuno Lehmann
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

peritoneal metastasis
locoregional treatment
pathophysiology

Published Papers (6 papers)

Download All Papers

Research

Jump to: Review

14 pages, 3248 KiB

Open AccessArticle

Near Infrared Fluorescence Imaging of Intraperitoneal Ovarian Tumors in Mice Using Erythrocyte-Derived Optical Nanoparticles and Spatially-Modulated Illumination

by Joshua M. Burns, Elise Shafer, Raviraj Vankayala, Vikas Kundra and Bahman Anvari

Cancers 2021, 13(11), 2544; https://doi.org/10.3390/cancers13112544 - 22 May 2021

Cited by 8 | Viewed by 2347

Abstract

Ovarian cancer is the deadliest gynecological cancer. Cytoreductive surgery to remove primary and intraperitoneal tumor deposits remains as the standard therapeutic approach. However, lack of an intraoperative image-guided approach to enable the visualization of all tumors can result in incomplete cytoreduction and recurrence. We engineered nano-sized particles derived from erythrocytes that encapsulate the near infrared (NIR) fluorochrome, indocyanine green, as potential imaging probes for tumor visualization during cytoreductive surgery. Herein, we present the first demonstration of the use of these nanoparticles in conjunction with spatially-modulated illumination (SMI), at spatial frequencies in the range of 0–0.5 mm⁻¹, to fluorescently image intraperitoneal ovarian tumors in mice. Results of our animal studies suggest that the nanoparticles accumulated at higher levels within tumors 24 h post-intraperitoneal injection as compared to various other organs. We demonstrate that, under the imaging specifications reported here, use of these nanoparticles in conjunction with SMI enhances the fluorescence image contrast between intraperitoneal tumors and liver, and between intraperitoneal tumors and spleen by nearly 2.1, and 3.0 times, respectively, at the spatial frequency of 0.2 mm⁻¹ as compared to the contrast values at spatially-uniform (non-modulated) illumination. These results suggest that the combination of erythrocyte-derived NIR nanoparticles and structured illumination provides a promising approach for intraoperative fluorescence imaging of ovarian tumor nodules at enhanced contrast. Full article

(This article belongs to the Special Issue Pathophysiology and Treatment of Peritoneal Metastasis)

► Show Figures

Graphical abstract

12 pages, 844 KiB

Open AccessArticle

Twelve-Year Single Center Experience Shows Safe Implementation of Developed Peritoneal Surface Malignancy Treatment Protocols for Gastrointestinal and Gynecological Primary Tumors

by Philipp Horvath, Can Yurttas, Stefan Beckert, Alfred Königsrainer and Ingmar Königsrainer

Cancers 2021, 13(10), 2471; https://doi.org/10.3390/cancers13102471 - 19 May 2021

Cited by 3 | Viewed by 1944

Abstract

(1) Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy provide survival benefits to selected patients. We aimed to report our experience and the evolution of our peritoneal surface malignancy program. (2) Methods: From June 2005 to June 2017, 399 patients who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at the Tübingen University Hospital were analyzed from a prospectively collected database. (3) Results: Peritoneal metastasis from colorectal cancer was the leading indication (group 1: 28%; group 2: 32%). The median PCI was 15.5 (range, 1–39) in group 1 and 11 (range, 1–39) in group 2 (p = 0.002). Regarding the completeness of cytoreduction (CC), a score of 0 was achieved in 63% vs. 69% for group 1 and 2, respectively (p = 0.010). Median overall survival rates for patients in group 1 and 2 for colon cancer, ovarian cancer, gastric cancer and appendix cancer were 34 and 25 months; 45 months and not reached; 30 and 16 months; 39 months and not reached, respectively. The occurrence of grade-III and -IV complications slightly differed between groups (14.5% vs. 15.6%). No 30-day mortality occurred. (4) Conclusions: Specialized centers are able to provide low-morbidity cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without mortality. Strict patient selection during the time period significantly improved CC scores. Full article

(This article belongs to the Special Issue Pathophysiology and Treatment of Peritoneal Metastasis)

► Show Figures

Graphical abstract

18 pages, 3312 KiB

Open AccessArticle

Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice

by Rens Braster, Marijn Bögels, Hreinn Benonisson, Manfred Wuhrer, Rosina Plomp, Arthur E. H. Bentlage, Rianne Korthouwer, Remco Visser, J. Sjef Verbeek, Marjolein van Egmond and Gestur Vidarsson

Cancers 2021, 13(10), 2372; https://doi.org/10.3390/cancers13102372 - 14 May 2021

Cited by 7 | Viewed by 3375

Abstract

Promising strategies for maximizing IgG effector functions rely on the introduction of natural and non-immunogenic modifications. The Fc domain of IgG antibodies contains an N-linked oligosaccharide at position 297. Human IgG antibodies lacking the core fucose in this glycan have enhanced binding to human (FcγR) IIIa/b, resulting in enhanced antibody dependent cell cytotoxicity and phagocytosis through these receptors. However, it is not yet clear if glycan-enhancing modifications of human IgG translate into more effective treatment in mouse models. We generated humanized hIgG1-TA99 antibodies with and without core-fucose. C57Bl/6 mice that were injected intraperitoneally with B16F10-gp75 mouse melanoma developed significantly less metastasis outgrowth after treatment with afucosylated hIgG1-TA99 compared to mice treated with wildtype hhIgG1-TA99. Afucosylated human IgG1 showed stronger interaction with the murine FcγRIV, the mouse orthologue of human FcγRIIIa, indicating that this glycan change is functionally conserved between the species. In agreement with this, no significant differences were observed in tumor outgrowth in FcγRIV^-/- mice treated with human hIgG1-TA99 with or without the core fucose. These results confirm the potential of using afucosylated therapeutic IgG to increase their efficacy. Moreover, we show that afucosylated human IgG1 antibodies act across species, supporting that mouse models can be suitable to test afucosylated antibodies. Full article

(This article belongs to the Special Issue Pathophysiology and Treatment of Peritoneal Metastasis)

► Show Figures

Graphical abstract

Review

Jump to: Research

14 pages, 879 KiB

Open AccessReview

Peritoneal Metastasis: Current Status and Treatment Options

by Lilian Roth, Linda Russo, Sima Ulugoel, Rafael Freire dos Santos, Eva Breuer, Anurag Gupta and Kuno Lehmann

Cancers 2022, 14(1), 60; https://doi.org/10.3390/cancers14010060 - 23 Dec 2021

Cited by 20 | Viewed by 4271

Abstract

Peritoneal metastasis (PM) originating from gastrointestinal cancer was considered a terminal disease until recently. The advent of better systemic treatment, a better understanding of prognostic factors, and finally, the advent of novel loco-regional therapies, has opened the door for the multimodal treatment of PM. These strategies, including radical surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) showed surprisingly good results, leading to the prolonged survival of patients with peritoneal metastasis. This has triggered a significant body of research, leading to the molecular characterization of PM, which may further help in the development of novel treatments. This review summarizes current evidence on peritoneal metastasis and explores potential novel mechanisms and therapeutic approaches to treat patients with peritoneal metastasis. Full article

(This article belongs to the Special Issue Pathophysiology and Treatment of Peritoneal Metastasis)

► Show Figures

Figure 1

19 pages, 970 KiB

Open AccessReview

Novel Perspectives in Pseudomyxoma Peritonei Treatment

by Antonio Sommariva, Marco Tonello, Giulia Rigotto, Nayana Lazzari, Pierluigi Pilati and Maria Luisa Calabrò

Cancers 2021, 13(23), 5965; https://doi.org/10.3390/cancers13235965 - 27 Nov 2021

Cited by 9 | Viewed by 4502

Abstract

Pseudomyxoma Peritonei (PMP) is an anatomo-clinical condition characterized by the implantation of neoplastic cells on peritoneal surfaces with the production of a large amount of mucin. The rarity of the disease precludes the evaluation of treatment strategies within randomized controlled trials. Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has proven to be the only therapeutic option with potential chances of cure and long-term disease control. The present review discusses the epidemiology, pathogenesis, clinical presentation and treatment of PMP, focusing on the molecular factors involved in tumor progression and mucin production that could be used, in the upcoming future, to improve patient selection for surgery and to expand the therapeutic armamentarium. Full article

(This article belongs to the Special Issue Pathophysiology and Treatment of Peritoneal Metastasis)

► Show Figures

Figure 1

24 pages, 3953 KiB

Open AccessReview

Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges

by Roxan F. C. P. A. Helderman, Daan R. Löke, Pieter J. Tanis, Jurriaan B. Tuynman, Wim Ceelen, Ignace H. de Hingh, Kurt van der Speeten, Nicolaas A. P. Franken, Arlene L. Oei, H. Petra Kok and Johannes Crezee

Cancers 2021, 13(14), 3430; https://doi.org/10.3390/cancers13143430 - 8 Jul 2021

Cited by 14 | Viewed by 3542

Abstract

Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments. Full article

(This article belongs to the Special Issue Pathophysiology and Treatment of Peritoneal Metastasis)

► Show Figures